Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01455896
Other study ID # ITCA 650-CLP-107
Secondary ID
Status Completed
Phase Phase 3
First received October 18, 2011
Last updated January 26, 2017
Start date March 2013
Est. completion date March 2016

Study information

Verified date January 2017
Source Intarcia Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 3 study to Evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650.


Recruitment information / eligibility

Status Completed
Enrollment 4156
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria:

- HBA1c > 6.5%

- History of coronary, cerebrovascular or peripheral artery disease

Exclusion Criteria:

- history of pancreatitis

Study Design


Intervention

Drug:
ITCA 650
ITCA 650
Other:
ITCA placebo
ITCA placebo

Locations

Country Name City State
United States Study Site Austin Texas
United States Study Site Avon Indiana
United States Study Site Billings Montana
United States Study Site Bradenton Florida
United States Study Site Chandler Arizona
United States Study Site Chicago Illinois
United States Study Site Cincinnati Ohio
United States Study Site Columbus Ohio
United States Study Site Dallas Texas
United States Study Site Evansville Indiana
United States Study Site Franklin Indiana
United States Study Site Franklin Ohio
United States Study Site Greenfield Indiana
United States Study Site Greer South Carolina
United States Intarcia Therapeutics, Inc Hayward California
United States Study Site Las Vegas Nevada
United States Study Site Long Beach California
United States Study Site Metaire Louisiana
United States Study Site Muncie Indiana
United States Study Site New Port Richey Florida
United States Study Site Newton Kansas
United States Study Site Palm Harbor Florida
United States Study Site Pittsburgh Pennsylvania
United States Study Site Port Hueneme California
United States Study Site Rochester Michigan
United States Study Site San Antonio Texas
United States Study SIte San Diego California
United States Study Site St Louis Missouri
United States Study Site Uniontown Pennsylvania
United States Study Site Wichita Kansas
United States Study Site Wichita Kansas
United States Study Site Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Intarcia Therapeutics

Countries where clinical trial is conducted

United States,  Bulgaria,  Denmark,  Finland,  Germany,  Poland,  Slovakia,  South Africa,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina), 2 years
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A